These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23448275)

  • 1. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
    Aihara Y; Yoshiji H; Noguchi R; Kaji K; Namisaki T; Shirai Y; Douhara A; Moriya K; Kawaratani H; Fukui H
    Hepatol Res; 2013 Nov; 43(11):1241-50. PubMed ID: 23448275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.
    Noguchi R; Yoshiji H; Ikenaka Y; Kaji K; Shirai Y; Aihara Y; Yamazaki M; Namisaki T; Kitade M; Yoshii J; Yanase K; Kawaratani H; Tsujimoto T; Fukui H
    Int J Mol Med; 2010 Sep; 26(3):407-13. PubMed ID: 20664958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
    Noguchi R; Yoshiji H; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Namisaki T; Kitade M; Douhara A; Moriya K; Fukui H
    Hepatol Res; 2013 Jul; 43(7):765-74. PubMed ID: 23163573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice.
    Kishina M; Koda M; Kato J; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Hepatol Res; 2014 Aug; 44(8):888-896. PubMed ID: 23777387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
    Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
    Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
    J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
    Okura Y; Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Noguchi R; Nishimura N; Seki K; Kawaratani H; Takaya H; Sato S; Sawada Y; Shimozato N; Furukawa M; Nakanishi K; Saikawa S; Kubo T; Asada K; Yoshiji H
    Hepatol Res; 2017 Nov; 47(12):1317-1328. PubMed ID: 28029729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
    Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of renin-angiotensin system in antifibrotic therapy.
    Yoshiji H; Kuriyama S; Fukui H
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S93-5. PubMed ID: 17567477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development.
    Yoshiji H; Kuriyama S; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Yoshii J; Yanase K; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Hepatol Res; 2006 Oct; 36(2):124-9. PubMed ID: 16919500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.
    Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Tsujinoue H; Nakatani T; Imazu H; Yanase K; Kuriyama S; Fukui H
    J Hepatol; 2002 Jul; 37(1):22-30. PubMed ID: 12076858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model.
    Seki K; Kitade M; Nishimura N; Kaji K; Asada K; Namisaki T; Moriya K; Kawaratani H; Okura Y; Takaya H; Sawada Y; Sato S; Nakanishi K; Yoshiji H
    Oncotarget; 2018 Jun; 9(47):28638-28651. PubMed ID: 29983886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
    Kitade M; Yoshiji H; Kojima H; Ikenaka Y; Noguchi R; Kaji K; Yoshii J; Yanase K; Namisaki T; Asada K; Yamazaki M; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Hepatology; 2006 Oct; 44(4):983-91. PubMed ID: 17006938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
    J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
    Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.
    Kochi T; Shimizu M; Terakura D; Baba A; Ohno T; Kubota M; Shirakami Y; Tsurumi H; Tanaka T; Moriwaki H
    Cancer Lett; 2014 Jan; 342(1):60-9. PubMed ID: 23981577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Anticancer Res; 2005; 25(5):3335-40. PubMed ID: 16101147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
    Yoshiji H; Noguchi R; Ikenaka Y; Namisaki T; Kitade M; Kaji K; Shirai Y; Yoshii J; Yanase K; Yamazaki M; Tsujimoto T; Kawaratani H; Akahane T; Aihara Y; Fukui H
    BMC Res Notes; 2009 May; 2():70. PubMed ID: 19416517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.